MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.

The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future..

Phase 3 trial shows a 4-fold rise in neutralizing antibodies 14 days after vaccination in adults 18-64 and 65+ with prior vaccine exposure. No new safety issues were found; the LP.8.1 vaccine shows a consistent profile in high-risk individuals.

A 76.3% overall response rate and a 100% disease control rate were seen in 38 evaluable ES-SCLC patients. Median progression-free survival of 6.8 months with tumor shrinkage averaging 56.7%. Get the data-driven signals to profit from September volatility ( for free ) →

The company might be close to commercializing its most advanced pipeline program.